A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Canada
Cisplatin
/ adverse effects
Deoxycytidine
/ adverse effects
Depsipeptides
/ administration & dosage
Dexamethasone
/ adverse effects
Female
Humans
Lymphoma, Large B-Cell, Diffuse
/ diagnosis
Lymphoma, T-Cell, Peripheral
/ diagnosis
Male
Middle Aged
Prognosis
Treatment Outcome
Non-Hodgkin lymphoma
combination therapy
phase I trial
romidepsin
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
12
10
2018
medline:
23
6
2020
entrez:
11
10
2018
Statut:
ppublish
Résumé
We investigated GDP (gemcitabine, 1000 mg/m
Identifiants
pubmed: 30301414
doi: 10.1080/10428194.2018.1515937
doi:
Substances chimiques
Depsipeptides
0
Deoxycytidine
0W860991D6
Dexamethasone
7S5I7G3JQL
romidepsin
CX3T89XQBK
Cisplatin
Q20Q21Q62J
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM